

# Best of ASCO® 2018 in Japan

a program licensed by the American Society of Clinical Oncology, Inc.

## プログラム

※本セミナーでとりあげる演題は、2018年6月1日～6月5日に開催される米国臨床腫瘍学会（ASCO）の年次総会の演題の中から重要なものをASCOのプログラム委員会が指定し、日本臨床腫瘍学会のBest of ASCO部会が選定したものです。但し、IDに \* 印のある演題は日本臨床腫瘍学会のBest of ASCO部会が独自で選定したものです。

7月7日（土曜日）

as of 2018/06/21

Time	講師	司会	ASCO演題		
9:30	開場		ID	Abstract Title	Author
10:30-10:40	<b>Welcome &amp; Introduction</b> 清田 尚臣 神戸大学医学部附属病院 / Best of ASCO部会 副部長				
10:40-11:15	<b>乳がん - Local/Regional/Adjuvant</b>		LBA1	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score.	Joseph Sparano
	松本 光史 兵庫県立がんセンター	佐治 重衡 福島県立医科大学	500	Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.	Michael Gnant
			506	PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.	Helena Earl
11:15-11:25	Discussion: Q&A				
11:25-11:55	<b>乳がん - Metastatic</b>		1000	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3.	Dennis Slamon
	尾崎 由記範 虎の門病院	藤澤 知巳 群馬県立がんセンター	LBA1006	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.	Jose Baselga
			1007	AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.	Peter Schmid
11:55-12:05	Discussion: Q&A				
12:05-12:25	<b>Developmental Therapeutics/Precision Medicine</b>		102	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.	Alexander Drilon
	久保木 恭利 国立がん研究センター東病院	川上 尚人 近畿大学医学部附属病院	12011*	WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies.	Jordi Rodon, MD, PhD
12:25-12:35	Discussion: Q&A				
12:35-12:50	Break 15分				
12:50-13:50	<b>【演者】</b> 各務 博 埼玉医科大学国際医療センター	<b>【座長】</b> 山本 信之 和歌山県立医科大学	<b>ランチョンセミナー</b> 進化する免疫チェックポイント阻害薬治療 共催：中外製薬株式会社		
13:50-14:10	Coffee Break 20分				
14:10-14:30	<b>頭頸部がん</b>		6000	Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.	Vijay Patil
	清田 尚臣 神戸大学医学部附属病院	門脇 重憲 愛知県がんセンター中央病院	6009	A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).	Sean McBride
14:30-14:40	Discussion: Q&A				
14:40-15:10	<b>婦人科がん</b>		5500	Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602.	Takashi ONDA
	温泉川 真由 がん研究会有明病院	原野 謙一 国立がん研究センター東病院	5506	Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.	Sandro Pignata
			5501*	A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.	Robert L. Coleman, MD
15:10-15:20	Discussion: Q&A				
15:20-15:40	<b>Sarcoma</b>		LBA2*	Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).	Gianni Bisogno, MD
	公平 誠 公平病院	清田 尚臣 神戸大学医学部附属病院			
15:40-15:50	Discussion: Q&A				
15:50-16:05	Break 15分				
16:05-16:50	<b>【演者】</b> 関 順彦 帝京大学	<b>【座長】</b> 酒井 洋 埼玉県立がんセンター	<b>スイーツセミナー</b> PD-1阻害剤の将来展望～最新のエビデンスを中心に～ 共催：MSD株式会社／大鵬薬品工業株式会社		
16:50-17:05	Break 15分				
17:05-17:25	<b>消化器がん - Gastrointestinal Cancer</b>		4062*	Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.	Charles S. Fuchs, MD
	川上 尚人 近畿大学医学部附属病院	砂川 優 聖マリアンナ医科大学	4007*	A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).	Yasuhiro Kodera, MD
17:25-17:35	Discussion: Q&A				
17:35-18:05	<b>消化器がん - Hepatobiliary / Pancreas Cancer</b>		LBA4001	Unicancer GI PRODIGE 24/CTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.	Thierry Conroy
	上野 誠 神奈川県立がんセンター	森実 千種 国立がん研究センター中央病院	4003*	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.	Andrew X. Zhu, MD, PhD
			4004	A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).	Pamela Kunz
18:05-18:15	Discussion: Q&A				

**Best of ASCO® 2018 in Japan**  
a program licensed by the American Society of Clinical Oncology, Inc.

7月8日 (日曜日)

Time	講師	司会	ASCO演題		
7:30	開場		ID	Abstract Title	Author
8:00-8:45	<b>【演者】</b> 平田 泰三 呉医療センター 中国がんセンター	<b>【座長】</b> 高松 泰 福岡大学	<b>モーニングセミナー</b> オピオイド誘発性便秘症治療の現状とこれからの期待 ~スインプロイクの使用経験を踏まえて~ 共催：塩野義製薬株式会社		
8:45-9:00	Break 15分				
9:00-9:30	<b>免疫療法</b>				
	北野 滋久 国立がん研究センター中央病院	石塚 賢治 鹿児島大学	3000	ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers.	Timothy Yap
			8008	FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response.	Aviva Krauss
			3006	NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.	Adi Diab, MD
9:30-9:40	Discussion: Q&A				
9:40-10:10	<b>泌尿器がん</b>				
	近藤 千紘 虎の門病院	田畑 健一 北里大学	LBA3	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.	Arnaud Mejean
			4503	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).	Arlene O. Siefker-Radtke, MD
			5007	KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).	Johann De Bono
10:10-10:20	Discussion: Q&A				
10:20-10:35	Break(15分)				
10:35-11:05	<b>血液がん</b>				
	山内 寛彦 国立がん研究センター東病院	南 陽介 国立がん研究センター東病院	103	Impact of Next-Generation Sequencing (NGS) on Treatment Selection in Acute Myeloid Leukemia (AML).	Rita Assi
			7500	RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.	Nathan Fowler
			3003	Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Refractory Large B Cell Lymphoma.	Frederick Locke
11:05-11:15	Discussion: Q&A				
11:15-11:35	<b>Patient and Survivor Care</b>				
	藤阪 保仁 大阪医科大学附属病院	井上 彰 東北大学大学院	10001	The effect of acupuncture versus cognitive behavior therapy on insomnia in cancer survivors: A randomized clinical trial.	Jun J. Mao, MD
			10005	Randomized Trial of a Symptom Monitoring Intervention for Hospitalized Patients with Cancer.	Charn-Xin Fuh
11:35-11:45	Discussion: Q&A				
11:45-12:00	Break 15分				
12:00-13:00	<b>【演者】</b> 岡本 勇 九州大学病院	<b>【座長】</b> 瀬戸 貴司 九州がんセンター	<b>ランチョンセミナー</b> 進行非小細胞肺癌における免疫チェックポイント阻害剤と殺細胞性抗がん剤の役割 共催：日本イーライリリー株式会社		
13:00-13:15	Coffee Break 15分				
13:15-13:35	<b>Melanoma</b>				
	並川 健二郎 国立がん研究センター中央病院	小野澤 祐輔 静岡県立静岡がんセンター	9501	Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.	Ulrike M. Leiter, MD
			9504	Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma.	Reinhard Dummer
13:35-13:45	Discussion: Q&A				
13:45-14:25	<b>肺がん - Immunotherapy</b>				
	三浦 理 新潟県立がんセンター	村上 晴泰 静岡県立静岡がんセンター	105	Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel with pembrolizumab or placebo for patients with metastatic squamous non-small cell lung cancer (NSCLC).	Luis Paz-Ares
			LBA9000	IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC.	Robert Jotte
			9001	Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): additional endpoints from the randomized phase 3 CheckMate 227 study.	Hossein Borghaei
			LBA4	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.	Gilberto Lopes
14:25-14:40	Discussion: Q&A				
14:40-15:00	<b>肺がん - Chemotherapy / Targeted Therapy</b>				
	林 秀敏 近畿大学	村上 晴泰 静岡県立静岡がんセンター	9006	Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026.	Naoki Furuya
			9005*	Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).	Atsushi Nakamura
15:00-15:10	Discussion: Q&A				
15:10-15:20	<b>Closing Remarks</b> 佐治 重衡 福島県立医科大学 / Best of ASCO部会 部会長				